Edgewood Oncology

Executive Summary

Edgewood Oncology is a private, San Diego-based biotechnology company focused on developing BTX-A51, a small molecule with a synergistic mechanism of action targeting both AML and solid tumors. Founded in 2020, the company leverages a precision medicine approach to identify patient populations most likely to benefit from its lead candidate. BTX-A51 has shown promising safety and anti-tumor activity in Phase 1 trials across both hematologic and solid tumor indications, and Edgewood plans to advance the compound further using biomarker-driven strategies. While the company has not disclosed its total funding or valuation, its focus on a de-risked asset with early clinical validation positions it as a potential player in the targeted oncology space. The upcoming catalysts include data updates from ongoing Phase 1 studies, potential initiation of Phase 2 trials in biomarker-selected populations, and possible partnership opportunities to expand development. With a lean structure and a clear precision medicine strategy, Edgewood Oncology represents an early-stage opportunity in the oncology small molecule landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data update from AML and solid tumor cohorts60% success
• Q4 2026Initiation of Phase 2 trial in a biomarker-selected population40% success
• TBDAnnouncement of a strategic partnership or financing round30% success